No services found
No Products found
100ug, 1MG
Human IgG1
ProteoGenix
Primary Antibodies
Monoclonal Antibody
Mammalian cells
Elisa, WB
Lirilumab has been investigated for the treatment of Leukemia, Cancer, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia.
Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Immobilized CD158a / KIR2DL1, C-His, recombinant protein (cat. No.PX-P5573) at 0.5µg/mL (100µL/well) can bind to Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb (cat. No.PX-TA1297) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Publication
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? * WB ELISA Sandwich ELISA IF IHC IP FC other
Did it work in your application? * Yes No
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Related products
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.